Advanced therapies is the umbrella over medicine's newest production systems: cell and gene therapies, mRNA therapeutics and RNA therapeutics, gene editing, and the personalized medicine programs that make a product for one patient. The craft is defined less by biology than by manufacturing logic, whether a therapy is a batch, a banked cell line, or a bespoke sequence printed for a single tumor genome. Regulation follows the same logic, with dedicated ATMP pathways for gene therapy, somatic cell therapy and tissue-engineered products .
The pipeline keeps deep while the business layer consolidates. The ASGCT-Citeline Q4 2025 report counts 1,248 RNA therapies in development, notes the approval of Arrowhead's siRNA therapy Redemplo for familial chylomicronemia syndrome, and records the quarter's acquisitions: Novartis committing up to USD 12 billion for Avidity Biosciences and Sanofi USD 2.2 billion for Dynavax . The scarce people are the ones who can build and run these systems, and consolidation concentrates them further.
Challenges in Advanced Therapies Recruiting
Cell and gene therapies passed the first wave into a crowded middle
The modality class has proven itself and entered the harder phase. ASGCT-Citeline data shows the development pipeline contracting modestly through Q4 2025 even as approvals continued, with a gene therapy and a CAR-T therapy approved in China and an siRNA approved in the United States in the same quarter . The acquisitions tell the economic story: platform companies are being absorbed before their products reach the market .
The hiring consequence is a two-tier bench. First-wave specialists with commercial approvals on their CVs sit inside the acquiring companies and rarely move; second-wave talent comes from preclinical and Phase 1 programs that keep being reorganized. Between them sits the crowded middle of the industry, dozens of companies running the same platform biology with different target lists. The umbrella also pulls in the older ATMP classes, regenerative medicine and tissue engineering among them, which recruit from entirely different benches under the same sector label . A brief written for the modality gets flooded with the middle; a brief written for the approval experience finds almost nobody.
mRNA therapeutics rebalanced from vaccines into individualized programs
The mRNA vaccine era compressed and now the field is rebuilding itself around therapeutic programs. The pipeline data shows mRNA declining quarter over quarter through 2025 while RNAi climbs, a rebalancing ASGCT attributes to shaken confidence in the modality's near-term commercial path . Where mRNA has momentum is precisely where a vaccine never went: individualized cancer vaccines. The NCI describes how BioNTech's autogene cevumeran encodes up to 20 neoantigens per patient, mRNA constructed from each patient's own tumor sequences .
That pivot redefines the talent pool. Vaccine programs hired at scale on one formulation and one dose schedule; individualized mRNA therapeutics need per-patient sequence-to-mRNA workflows, small-batch manufacturing under time pressure, and release testing on products that exist once. The people who built the vaccine plants do not automatically become the people who build the individualized ones, and the market keeps pricing them as if they did. The sequencing-to-mRNA chain also imports a second craft entirely: tumor informatics people who can call variants against a patient's normal genome before the therapeutic decision is even made .
RNA therapeutics split into chemistries that do not share a bench
RNA therapeutics is one label over three crafts. siRNAs silence transcripts through the RNAi pathway, antisense oligonucleotides bind and cleave or block, and mRNA instructs translation, and each carries its own chemistry: phosphorothioate backbones, GalNAc conjugation, morpholino replacements, ionizable lipids. DelveInsight counts more than 90 antisense oligonucleotide candidates across over 70 active companies, with the majority of ASO, RNAi and mRNA pipelines still preclinical .
The bench split is practical. Oligonucleotide synthesis is solid-phase chemistry with scale-up economics of its own; LNP formulation is colloid science; and the biology side runs on target validation and delivery questions that differ per chemistry. A scientist who has spent a decade optimizing RNAi for the liver has never designed a splice-switching ASO, and the CV rarely makes the distinction legible. Hiring across this field without naming the chemistry is the fastest way to fill an interview loop with the wrong specialists.
Personalized medicine turns the therapy into a per-patient supply chain
The individualized programs collapse the line between therapy and logistics. The neoantigen vaccine workflow runs from tumor biopsy through nucleic acid isolation, tumor and normal sequencing, variant calling, neoantigen prediction, vaccine design, manufacture and release testing, with the whole sequence taking three to six months even when expedited . Every patient is a batch, every batch has its own sequence file, and the release criteria must hold for products that will never be made again.
That structure hires differently. Program managers who can move sequencing, prediction, manufacturing and regulatory documentation in parallel are the binding constraint, more than any single scientist. The regulatory layer is its own craft: EMA's ATMP framework classes gene therapy, somatic cell therapy and tissue-engineered products separately, and an individualized product has to be filed with a comparability argument that batch-based medicines never need . The intersection of per-patient manufacturing and ATMP regulation is staffed by a very small group.
CAR-T therapies moved from hematology to a decentralized question
CAR-T therapies are the most industrialized corner of advanced therapies, and their frontier is now a manufacturing debate. The ex vivo model, autologous cells engineered in a central facility, works but is slow and capacity-bound; the alternatives, allogeneic off-the-shelf banks, point-of-care manufacturing, and in vivo engineering that skips the facility entirely, each claim the same patients. ASGCT-Citeline Q2 2026 data shows the direction of travel: eleven new CAR-T programs using mRNA-encoded chimeric antigen receptors appeared in a single quarter, matching the total reported across all of 2025 .
Each model hires from a different population. Ex vivo teams come from cell processing and apheresis logistics; allogeneic teams from cell banking and genome engineering of donor lines; in vivo teams from mRNA delivery and gene editing, which is to say from a completely different discipline. The in vivo route is the newest and thinnest bench, because it demands the union the rest of the field spent a decade separating: delivery science and editing biology in one program. A company running all three bets is assembling three teams that share a therapeutic area and almost no tooling, and the title CAR-T does not sort them.
Personalized medicine claims settle at the per-patient batch
Verification in this field starts from what only the owner knows. Ask an mRNA scientist which LNP formulation they took through repeat dosing and what the immunogenicity data showed. Ask an oligonucleotide chemist which modifications they conjugated and what the synthesis yield was at what scale. Ask a neoantigen program person how long their last patient-specific vaccine took from biopsy to release, and where the three to six months actually went .
The cost of a miss is structural. In advanced therapies the batch is the therapy, and in personalized medicine the batch is also the patient, so a failed release or an unvalidated prediction step stalls a program in units that cannot be re-run . That is the discipline's hiring math: the assessment has to be as specific as the manufacturing, because the mistakes arrive one patient at a time.
References
- Gene, Cell, and RNA Therapy Landscape Report Q4 2025 — American Society of Gene & Cell Therapy (ASGCT) and Citeline. (accessed 2026-09-28)
- Neoantigen Vaccines Keep Kidney, Pancreatic Cancer at Bay — National Cancer Institute (NCI). (accessed 2026-09-28)
- Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline 2025 — DelveInsight. (accessed 2026-09-28)
- Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy — npj Vaccines (PMC). (accessed 2026-09-28)
- Advanced therapy medicinal products: Overview — European Medicines Agency (EMA). (accessed 2026-09-28)
- Gene, Cell, and RNA Therapy Landscape Report Q2 2026 — American Society of Gene & Cell Therapy (ASGCT) and Citeline. (accessed 2026-09-28)